{
    "clinical_study": {
        "@rank": "21714", 
        "acronym": "APPLE", 
        "arm_group": {
            "arm_group_label": "Adenosine arm", 
            "arm_group_type": "Active Comparator", 
            "description": "After pulmonary vein isolation, 12mg Iv adenosine will be given to treatment group, will evaluate pulmonary vein reconnection."
        }, 
        "brief_summary": {
            "textblock": "The investigators studied the effects of adenosine on the reconnection rate  after\n      successful pulmonary veins isolation by radiofrequency catheter ablation  in patients with\n      drug-resistant atrial fibrillation"
        }, 
        "brief_title": "Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Persistent Common Pulmonary Vein"
        ], 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "Pulmonary vein isolation has emerged as an effective therapy for paroxysmal atrial\n      fibrillation. However, atrial fibrillation recurs in up to 50% of patients, generally\n      because of recovery of pulmonary vein conduction.\n\n      Adenosine given during the initial procedure may reveal dormant pulmonary vein conduction,\n      thereby identifying the need for additional ablation, leading to improved outcomes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed atrial fibrillation\n\n          -  recurrence of symptomatic atrial fibrillation in spite of Antiarrhythmic drug use\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  intracardiac thrombus\n\n          -  pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932112", 
            "org_study_id": "APPLE"
        }, 
        "intervention": {
            "arm_group_label": "Adenosine arm", 
            "description": "After pulmonary vein isolation, 12mg Iv adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.", 
            "intervention_name": "Adenosine arm", 
            "intervention_type": "Drug", 
            "other_name": "APPLE"
        }, 
        "intervention_browse": {
            "mesh_term": "Adenosine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary Vein Isolation", 
            "Adenosin effect", 
            "Atrial fibrillation ablation"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "oys@catholic.ac.kr", 
                "last_name": "Yong Seog Oh, MD", 
                "phone": "82-2-2258-1141"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Seocho-Ku", 
                    "zip": "137-040"
                }, 
                "name": "Seoul st Mary's Hospital"
            }, 
            "investigator": {
                "last_name": "Yong Seog Oh, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)", 
        "overall_contact": {
            "email": "oys@catholic.ac.kr", 
            "last_name": "Yong Seog OH, MD", 
            "phone": "82-2-2258-1141"
        }, 
        "overall_official": {
            "affiliation": "Seoul St. Mary's Hospital", 
            "last_name": "Yong seog Oh, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "After pulmonary vein isolation, 12mg Iv adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.", 
            "measure": "Reconnection of pulmonary vein electrogram after adenosine infusion", 
            "safety_issue": "No", 
            "time_frame": "5 minutes after IV adenosine"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932112"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul St. Mary's Hospital", 
            "investigator_full_name": "Yong Seog Oh", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "At 1 month, 3 month, 6 month and 12 months post ablation routine clinic visits, will perform electrocardiographically documented by electrogram (At 1,3,6,12 months post ablation) and Holter monitoring (At 12 months post ablation)", 
            "measure": "Atrial fibrillation recurrence", 
            "safety_issue": "No", 
            "time_frame": "between 0 and 12 months"
        }, 
        "source": "Seoul St. Mary's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul St. Mary's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}